Recent news coverage relevant to Nordicus is primarily market-wide and macroeconomic, with no company-specific developments reported.

• Stocks were supported as bond yields slid following a weak CPI report, reflecting broader market conditions [N1].
• Ethereum cryptocurrency surged 6% on cooler inflation data, indicating market sensitivity to inflation trends [N2].
• Apple's 20th anniversary iPhone may feature a major redesign including a glass back, highlighting innovation in tech sectors [N3].
• Comparative revenue trends of tech companies DigitalOcean and Datadog were analyzed, providing insights into tech sector dynamics [N4].
• The US dollar declined while gold rallied as CPI data trailed estimates, affecting currency and commodity markets [N5].
• Stocks rallied on a Fed-friendly CPI report, indicating positive market sentiment [N6].
• Palantir's valuation at 64X sales was discussed, examining premium justification in tech valuations [N7].
• Natural gas prices consolidated above a recent two-month low, reflecting energy market movements [N8].

Nordicus' approach of acquiring and advancing early-stage Nordic biotech companies in areas with unmet medical needs offers potential for breakthrough therapeutics. The company has demonstrated progress with preclinical studies showing efficacy and safety in animal models for its lead products. Its diversified portfolio across oral disorders and immune diseases, combined with a structured value creation process and experienced management, supports potential value creation through clinical milestones and strategic exits.

Nordicus operates in a high-risk biotech segment with early-stage preclinical assets that have yet to demonstrate clinical efficacy in humans. The company reported a net loss and liquidity ratios indicating current liabilities exceed current assets, suggesting financial constraints. Clinical development timelines and regulatory approvals are uncertain, and failure to achieve key milestones could impair value. The company's reliance on acquisitions and all-stock transactions may dilute existing shareholders and complicate integration. Market and competitive risks in biotech also pose challenges.

Nordicus' moat is based on its strategic focus on the Nordic biotech ecosystem, leveraging regional scientific expertise and innovation. Its value creation process involves scouting, accelerating, acquiring, and exiting early-stage biotech companies, which may provide access to novel therapeutics in underserved medical areas. The company's portfolio diversification across multiple preclinical-stage subsidiaries targeting distinct oral and immune-mediated diseases aims to mitigate risk. However, as a smaller reporting company with early-stage assets, its competitive advantage depends on successful clinical development and execution of its value creation strategy.

• Clinical Development Risk: The company’s therapeutics are in preclinical or early clinical stages, with inherent risks of failure in safety, efficacy, or regulatory approval.
• Financial and Liquidity Risk: As of March 31, 2026, current liabilities exceed current assets with a current ratio of 0.46 and a cash ratio of 0.03, indicating potential liquidity constraints.
• Execution Risk: Successful advancement of portfolio companies through clinical phases and achieving milestones is critical; failure to do so may impact value creation.
• Market and Competitive Risk: The biotech sector is highly competitive and subject to rapid scientific and regulatory changes that may affect the company’s prospects.

• Nordicus Partners Corp is a U.S. publicly listed biotechnology company specializing in developing breakthrough therapeutics for diseases with unmet medical needs, focusing initially on oral disorders.
• The company targets innovative biotech companies in the Nordic region, known for strong life science ecosystems, and acquires and develops drugs from these companies.
• Nordicus employs a four-step value creation process: Scout and Accelerate, Acquire and Exit, aiming to take portfolio companies through Phase I clinical trials.
• The company has acquired 100% ownership of two Danish preclinical-stage biotech companies: Orocidin A/S (developing therapies for periodontitis) and Bio-Convert A/S (developing treatments for oral leukoplakia).
• Nordicus formed a third subsidiary, NoviThera ApS, in October 2025 to develop monoclonal antibody therapy for psoriasis, holding a 50.1% ownership interest.
• Orocidin's lead product, QR-01, has completed preclinical toxicology and efficacy studies in animals, showing good tolerance and improvements in periodontitis indicators.
• Bio-Convert's QR-02 compound targets oral leukoplakia, a potentially pre-cancerous oral condition with no approved medical treatments; it has received a toxicity waiver and is finalizing GMP production.
• NoviThera's QR-04 compound aims to develop a monoclonal antibody treatment for psoriasis, with biological proof of concept demonstrated in mice.
• Nordicus' portfolio diversification strategy aims to mitigate risk and provide upside potential.
• The company completed a 1-for-10 reverse stock split in November 2024 and changed its name to Nordicus Partners Corporation with ticker NORD in May 2023.
• As of March 31, 2026, Nordicus reported a net loss of $4,001,686 and basic and diluted EPS of -$0.22 per share.
• Financial snapshot as of March 31, 2026, shows current assets of $532,884 and current liabilities of $1,171,096, resulting in a current ratio of 0.46 and a cash ratio of 0.03, indicating liquidity constraints.
• The company is a smaller reporting company and is not subject to any pending legal proceedings as of the latest filings.
• Nordicus' board has been expanded and includes committees for governance, audit, and compensation, with established policies including a Code of Conduct and Ethics.
• The company is preparing for Phase IIa clinical trials for Orocidin and Bio-Convert in the first half of 2027 at the University of Copenhagen and in Europe respectively.